Nothing Special   »   [go: up one dir, main page]

US20020006417A1 - Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses - Google Patents

Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses Download PDF

Info

Publication number
US20020006417A1
US20020006417A1 US09/440,731 US44073199A US2002006417A1 US 20020006417 A1 US20020006417 A1 US 20020006417A1 US 44073199 A US44073199 A US 44073199A US 2002006417 A1 US2002006417 A1 US 2002006417A1
Authority
US
United States
Prior art keywords
fill mass
capsule
fill
mass
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/440,731
Other versions
US6352717B2 (en
Inventor
Rainer Alex
Jurgen Gerhards
Ingeborg Kraemer-Pittrof
Richard Oeschger
Thomas Rades
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann La Roche Inc
Original Assignee
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche Inc filed Critical Hoffmann La Roche Inc
Assigned to HOFFMANN-LA ROCHE INC. reassignment HOFFMANN-LA ROCHE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: F.HOFFMANN-LA ROCHE AG
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RADES, THOMAS, ALEX, RAINER, GERHARDS, JURGEN, KRAEMER-PITTROF, INGEBORG, OESCHGER, RICHARD
Publication of US20020006417A1 publication Critical patent/US20020006417A1/en
Application granted granted Critical
Publication of US6352717B2 publication Critical patent/US6352717B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/072—Sealing capsules, e.g. rendering them tamper-proof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/074—Filling capsules; Related operations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Definitions

  • gelatin capsules are used widely in the pharmaceutical industry. They can be applied as an oral dosage form, as a suppository dosage form for rectal use or for vaginal use, as a specialty package in tube form, for human and veterinary single dose application, in the cosmetic industry etc.
  • Their capsule shell is basically composed of gelatin and water; it may contain additional ingredients such as plasticisers, preservatives, colouring and opacifying agents, flavouring, sugars, acids, and medicaments to achieve desired effects.
  • Gelatin capsules can be used to dispense a variety of different active compounds.
  • the drug may be a liquid or at least dissolved, solubilised, or suspended in a liquid vehicle. Since the capsule fill mass is metered into individual capsules by a positive-displacement pump, a much higher degree of reproducibility is achieved than is possible with powder or granule feed in the manufacture of tablets and powder or granule filled hard gelatin capsule products.
  • capsule formulations allow more flexibility in the design of a dosage form to fit biopharmaceutical specifications of a particular therapeutic agent.
  • the gelatin mass is fed by gravity to a metering device (spreader box), which controls the flow of the mass onto air-cooled rotating drums.
  • a metering device preader box
  • Gelatin ribbons of controlled thickness are therefore formed.
  • the ribbons are fed through a lubricating bath, over guide rolls, and then down between an injection wedge (for the fill material) and die rolls.
  • the material to be encapsulated which has been previously mixed and stored, flows by gravity into a positive displacement pump.
  • the pump accurately meters the material through a leads and the wedge and into the gelatin ribbons between the die rolls.
  • the capsule is about half sealed when the pressure of the pumped material forces the gelatin into the die pockets, where the capsules are simultaneously filled, shaped, hermetically sealed and cut from the gelatin ribbon.
  • All fill masses e.g. liquids, solutions, and suspensions
  • All fill masses should preferably flow at room temperature and in any case at a temperature not exceeding 35° C. at the point of encapsulation, since the sealing temperature of the gelatin films must remain below this temperature.
  • the liquid fill mass can be prepared as described for the soft gelatin capsules process.
  • the empty capsules comprising a cap and a body portion, are oriented so that all point in the same direction (i.e. body-end downward).
  • the capsules pass one-at-a-time through a channel just wide enough to provide a frictional grip at the cap end.
  • a specially designed blade pushes against the capsule and causes it to rotate about its cap end as a fulcrum. After two pushes (one horizontally and one vertically downward), the capsules will always be aligned body-end downward, regardless of which end entered the channel first. At this point the caps are separated from the bodies.
  • the rectified capsules are delivered body-end first into the upper portion of split bushings or split filling rings.
  • a vacuum applied from below pulls the bodies down into the lower portion of the split bushing.
  • the diameter of the caps is too large to allow them to follow the bodies into the lower bushing portion.
  • the split bushings are then separated to expose the bodies for filling.
  • the body portion of the capsule can be thus filled with the fill mass which cannot exceed a temperature of 60° C.
  • the cap and body bushing portions are rejoined wherein pins are used to push the filled bodies up into the caps for closure, and to push the closed capsules out of the bushings.
  • Compressed air also may be used to eject the capsules.
  • hard gelatin capsules may be made hermetically by e.g. banding (i.e. layering down a film of gelatin, often distinctively colored, around the seam of the cap and body).
  • shear sensitive fill masses can totally or partially solidify before being encapsulated, or even in the capsules upon storage.
  • the solidification of the fill mass or of one or more components thereof is due to mechanical phenomena, such as the shear stress, which occurs at various points of the manufacturing process.
  • the most critical points of the process involve the mixing vessels and the pumps, wherein the shear stress dramatically increases with increasing viscosity of the fill mass.
  • This total or partial solidification can cause significant and unacceptable changes in the pharmaceutical quality of the product like, for example, reduction and variability of the capsules dissolution rate, and hence the bioavailability of the drug substance and the therapeutic effects of the drug.
  • the present invention provides a process for encapsulating a shear sensitive fill mass into a capsule, comprising the following steps in order:
  • a shear sensitive fill mass comprising an agent taken from the group consisting of pharmaceutical active agents and nutrients;
  • the present invention provides a capsule containing a shear sensitive fill mass which comprises an agent selected from the group fo pharmaceutically active agents and nutrients, wherein the fill mass is encapsulated in accordance wth the above process.
  • the present invention also provides a capsule containing a shear sensitive fill mass which comprises an agent selected from the group of pharmaceutically active agents and nutrients, wherein the capsule has a constant dissolution rate of at least 70% of the pharmaceutically active agent within 30 minutes after administration.
  • FIG. 1 a is a flow sheet diagram depicting the process according to the invention for manufacturing soft gelatin capsules
  • FIG. 1 b is a flow sheet diagram depicting the process according to the invention for manufacturing hard gelatin capsules
  • FIG. 2 is a rheogramm of the shear stress (Pa) over the shear rate (1/s) of three saquinavir soft gelatin capsules manufactured with the process of the invention;
  • FIG. 3 is a rheogramm of the shear stress (Pa) over the shear rate (1/s) of a saquinavir soft gelatin capsule (C 1 ) manufactured with the process of the invention, and of two saquinavir soft gelatin capsules (C 2 , C 3 ) obtained with the conventional process;
  • FIG. 4 is the dissolution profile of three saquinavir soft gelatin capsules manufactured with the process of the invention.
  • FIG. 5 is the dissolution profile of a saquinavir soft gelatin capsule (C 1 ) manufactured with the process of the invention, and of two saquinavir soft gelatin capsules (C 2 , C 3 ) obtained with the conventional process.
  • the present invention provides a process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses obtained by said process.
  • the fill mass comprises a pharmaceutically active agent or a nutrient.
  • capsule encompasses hard and soft shell capsules which are preferably used to administer nutrients or pharmaceutically active agents to individuals. Such capsules are soluble under physiological conditions, digestible or permeable.
  • the capsule shells are usually made of gelatin, starch, or other suitable physiologically acceptable macromolecular materials in form of gels. Examples thereof are soft gelatin capsules, hard gelatin capsules and Hydroxy Propyl Methyl Cellulose (HPMC) capsules.
  • a shear sensitive fill mass which undergoes the process of the present invention can be an emulsion, dispersion or solution including a supersaturated solution.
  • Suitable vehicles which can be used for preparing fill masses for encapsulation may be chosen among the aromatic and aliphatic hydrocarbons, chlorinated hydrocarbons, high-molecular-weight-alcohols, esters and organic acids, vegetable oils, mineral oil, silicon oil, non-ionic surface active agents, polyethylene glycols, medium chain triglycerides and medium chain mono and diglycerides, either alone or in combination.
  • the solid component of the shear sensitive fill mass which has formed due to shear stress during the mixing and pumping stages of the process, can be re-liquefied or re-dissolved by heating it.
  • the temperature to which the fill mass must be heated depends on the physical and chemical characteristics of the fill mass itself.
  • the fill mass is then cooled to below about the sealing temperature for the type of capsule being used, so that the temperature of the fill mass is below the sealing temperature of the capsule when the fill mass is placed in the capsule.
  • the homogeneous fill mass is cooled to below the stated temperature for each type of gelatin capsule, preferably to about room temperature. It has been surprisingly found that, once cooled, the homogeneous shear sensitive fill mass does not return to the solid or semi-solid state as long as it does not undergo further mechanical strain. According to the present invention, the encapsulation takes place within a sufficiently short amount of time after the heating and subsequent cooling of the shear sensitive fill mass so that the content of the capsule remains homogeneous over the life time of the encapsulated nutrient or pharmaceutical agent.
  • the heating and subsequent cooling of the fill mass takes place essentially immediately prior to encapsulation.
  • the amount of time from the cooling step to the encapsulation step can be from about 10 to 30 seconds, preferably from about 10 to about 20 seconds.
  • the heating and cooling of the fill mass can be carried out in conventional manners, e.g. by letting it flow through spiral tubes immersed in water/oil baths and cold water bath, respectively.
  • the contact time of the fill mass in the heating device can be varied by modifying the residence time in the bath, heating of the fill mass after it has been processed through the dosing pump is also suitable for thermolabile substances.
  • the process according to the present invention allows one to obtain capsules showing high and constant dissolution rates.
  • the amount of active agent encapsulated and administered to a patient can be therefore reduced since the active agent itself is rapidly dissolved.
  • the overall costs of the medicaments are thereby also reduced.
  • the high homogeneity (and therefore the high and constant dissolution rate) of the capsules produced with the process according to the present invention guarantees a reproducible bioavailability and therapeutic effect of an active agent which is contained in it.
  • the fill mass is preferably heated to a temperature between 0° C. and about 20° C. above its melting point, and subsequently cooled to a temperature between about 35° C. and about 20° C.
  • the fill mass is preferably heated to a temperature between 0° C. and about 20° C. above its melting point, and subsequently cooled to a temperature between about 60° C. and about 20° C.
  • the process according to the present invention is suitable for fill masses like, for instance, emulsions, dispersions and solutions comprising the pharmaceutically active agent(s), as well as for pure pharmaceutically active agents in the liquid state.
  • the process according to the present invention is suitable for fill masses comprising high doses of a sparingly soluble pharmaceutical agent such as e.g. a HIV protease inhibitor and, more particularly, for solutions of saquinavir.
  • a sparingly soluble pharmaceutical agent such as e.g. a HIV protease inhibitor and, more particularly, for solutions of saquinavir.
  • These particular fill masses can be heated to a temperature which is preferably in the range between about 70° C. and about 100° C. and then cooled to a temperature between about 35° C. and about 20° C., in the case of soft gelatin capsules, and between about 60° C. and about 20° C. in the case of hard gelatin capsules.
  • the process according to the present invention comprises the steps of:
  • step d) injecting the heated and subsequently cooled fill mass of step c) from the injection wedge into the capsules.
  • the fill mass undergoes heating also in the feed tank, at a temperature which is preferably between about 35° C. and about 95° C. In this way solidification of the fill mass in the dosing pump can be avoided, and any complete or partial solidification of the fill mass that has occurred prior to the dosing pump can be reversed.
  • heating of the feed tank reduces the viscosity of the fill mass and therefore reduces the risk and extent of solidification of the fill mass caused by shear stress in the dosing pump.
  • the fill mass undergoes heating in the dosing pump, at a temperature which is preferably between about 35° C. and about 80° C.
  • the heating of the dosing pump e.g. electrically, avoids solidification of the fill mass in the dosing pump or reverses solidification of the fill mass that has occurred prior to the dosing pump.
  • heating of the latter is also suitable for thermolabile substances.
  • the fill mass is heated in the feed tank, as well as in the dosing pump, preferably at the above temperatures.
  • the fill mass which flows from the dosing pump is heated and then cooled.
  • the dosed amounts are then passed into an injection wedge for subsequent injection into the capsules.
  • capsules are obtained wherein the shear sensitive fill mass remains highly homogeneous for at least six to twelve, or even up to about 24 months after production.
  • the capsules obtained according to the process of the invention contain a shear sensitive fill mass and have a constant dissolution rate, and release of at least 70% of the drug substance is achieved within 30 minutes after administration.
  • the capsules according to the present invention contain a shear sensitive fill mass and which have a constant dissolution rate of at least 70% of the drug substance within 30 minutes after administration.
  • the fill mass preferably contains, as active ingredient, a HIV protease inhibitor and, more preferably, a solution of saquinavir.
  • the fill mass is prepared in a mixing vessel 1 , wherein the active agent is dissolved, emulsified or suspended in an appropriate solvent, eventually together with antioxidants and/or other additives.
  • the so obtained solution, emulsion or suspension is transferred into a storage tank 2 , and then pumped into a feed tank 3 and heated by a water bath.
  • the fill mass is fed by gravity to an electrically heated dosing pump 4 controlling the flow of the mass which will be injected in the capsules.
  • the fill mass flowing out from the dosing pump 4 undergoes heating in a heating bath 5 (oil or water) and afterwards cooling in a cooling bath 6 (cold water) and is finally fed to a filling wedge 7 for injection into the capsule.
  • gelatin mass is fed by gravity to a metering device 8 which controls the flow of the mass onto rotating drums (not shown).
  • Gelatin ribbons 9 of controlled thickness are thus formed.
  • the ribbons 9 are fed through a lubricant bath (not shown), over guide rolls (not shown) and then down between the wedge 7 and die rolls 10 .
  • the fill mass is dosed, through orifices (not shown) of the wedge 7 into the gelatin ribbons 9 between the die rolls 10 , wherein the orifices are lined up with die pockets 11 of the die rolls 10 .
  • the capsule is about half sealed when the pressure of the pumped fill mass forces the gelatin into the die pockets 11 , where the capsules are simultaneously filled, shaped, hermetically sealed and cut from the gelatin ribbons 9 .
  • the sealing of the capsule is achieved by mechanical pressure on the die rolls 10 and by heating of the gelatin ribbons 9 by the wedge 7 .
  • the fill mass is dosed through orifices (not shown) of the wedge 7 into previously prepared hard gelatin shells 8 .
  • the filled hard gelatin capsules are then sealed.
  • Saquinavir gelatin capsules having the composition listed in Table 1 were prepared according to the process already described. TABLE 1a Composition of saquinavir soft gelatin capsule Ingredient mg/Capsule Capsule Fill: Saquinavir (amorphous) 200.00 Medium Chain Mono and Diglycerides 765.00 Povidone K 30 30.00 DL-alpha-Tocopherol 5.00 Mass of capsule contents 1000.00 Capsule Shell: Gelatin 250.92 Glycerol 85% 168.73 Titanium Dioxide 3.06 Yellow Iron Oxide 0.20 Red Iron Oxide 0.027 Mass of capsule shell 422.937
  • Table 3 shows the values of the content (C) of three soft gelatin capsules obtained with the process of the invention and of the content of three soft gelatin capsules obtained with a conventional process (i.e., without heating the fill mass in the feed tank or in or after the dosing pump).
  • Table 3 Optical Density (540 nm, 5 ⁇ 5 mm cell) and Light Scattering (500/500 nm, 5 ⁇ 5 mm cell).
  • Process according to Conventional Process the invention C1 C2 C3 C1 C2 C3 Optical Density 0.862 1.391 0.343 0.010 0.014 0.008 Light Scattering 34.3 23.8 23.8 0.010 0.010 0.000
  • the optical density and the light scattering values of the capsule content produced according to the above process are much lower than those obtained with conventional processes and, they are highly reproducible.
  • the saquinavir capsules of Table 3 obtained with the process of the present invention are therefore superior in their homogeneity and limpidity as compared to those obtained with conventional processes.
  • FIG. 5 depicts the much faster dissolution rate of C 1 , a capsule according to the invention, as compared to the dissolution rate of C 2 and C 3 which are two capsules made with the conventional technique.
  • FIG. 4 depicts the dissolution profile of three saquinavir soft gelatin capsules manufactured in accordance with the process of the present invention. The dissolution rate of the present saquinavir gelatin capsules is highly reproducible, as clearly shown in FIG. 4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Basic Packing Technique (AREA)
  • Confectionery (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention provides a process for encapsulating a shear sensitive fill mass which contains a pharmaceutical active agent or nutrient, characterised in that said fill mass is heated and subsequently cooled, prior to the encapsulation. The invention also provides capsules comprising shear sensitive fill material obtained by the said process which have a high and constant dissolution rate.

Description

    BACKGROUND OF THE INVENTION
  • Owing to their special properties and advantages, gelatin capsules are used widely in the pharmaceutical industry. They can be applied as an oral dosage form, as a suppository dosage form for rectal use or for vaginal use, as a specialty package in tube form, for human and veterinary single dose application, in the cosmetic industry etc. Their capsule shell is basically composed of gelatin and water; it may contain additional ingredients such as plasticisers, preservatives, colouring and opacifying agents, flavouring, sugars, acids, and medicaments to achieve desired effects. [0001]
  • Gelatin capsules can be used to dispense a variety of different active compounds. Several advantages of gelatin capsules derive from the fact that the drug may be a liquid or at least dissolved, solubilised, or suspended in a liquid vehicle. Since the capsule fill mass is metered into individual capsules by a positive-displacement pump, a much higher degree of reproducibility is achieved than is possible with powder or granule feed in the manufacture of tablets and powder or granule filled hard gelatin capsule products. The biopharmaceutical availability of drugs formulated as liquid filled gelatin capsules, as measured by disintegration time or dissolution rate, often shows an advantage over other solid dosage forms. The biopharmaceutical characteristics of such formulations can be altered or adjusted more easily than those of other dosage forms. Through the selection and use of liquids and combinations of liquids that range from water immiscible through emulsifiable to completely water-miscible, and by altering the type or quantity of thickening or suspending agents, capsule formulations allow more flexibility in the design of a dosage form to fit biopharmaceutical specifications of a particular therapeutic agent. [0002]
  • Mainly, two different kinds of gelatin capsules are commonly used, i.e. soft and hard gelatin capsules. [0003]
  • Several processes are known in the art for producing soft gelatin capsules. The most important is the rotary die process, which is a continuous flow process developed by Scherer first in 1933 (J. P. Stanley, [0004] The Theory and Practice of Industrial Pharmacy, 3rd Ed., 1986, p 398-412).
  • According to this process, the gelatin mass is fed by gravity to a metering device (spreader box), which controls the flow of the mass onto air-cooled rotating drums. Gelatin ribbons of controlled thickness are therefore formed. The ribbons are fed through a lubricating bath, over guide rolls, and then down between an injection wedge (for the fill material) and die rolls. The material to be encapsulated, which has been previously mixed and stored, flows by gravity into a positive displacement pump. The pump accurately meters the material through a leads and the wedge and into the gelatin ribbons between the die rolls. The capsule is about half sealed when the pressure of the pumped material forces the gelatin into the die pockets, where the capsules are simultaneously filled, shaped, hermetically sealed and cut from the gelatin ribbon. The sealing of the capsule is achieved by mechanical pressure on the die rolls and the heating of the ribbons by the wedge. All fill masses (e.g. liquids, solutions, and suspensions) for encapsulation should preferably flow at room temperature and in any case at a temperature not exceeding 35° C. at the point of encapsulation, since the sealing temperature of the gelatin films must remain below this temperature. [0005]
  • Several types of filling machines for hard gelatin capsules are known in the pharmaceutical industry (Larry L. Augsburger, Hard and Soft Shell Capsules, Modem Pharmaceutics, G. S. Banker, C. T. Rhodes (Eds.), Third Edition, Marcel Dekker Inc. (1996), 395-428). [0006]
  • The liquid fill mass can be prepared as described for the soft gelatin capsules process. The empty capsules, comprising a cap and a body portion, are oriented so that all point in the same direction (i.e. body-end downward). In general the capsules pass one-at-a-time through a channel just wide enough to provide a frictional grip at the cap end. A specially designed blade pushes against the capsule and causes it to rotate about its cap end as a fulcrum. After two pushes (one horizontally and one vertically downward), the capsules will always be aligned body-end downward, regardless of which end entered the channel first. At this point the caps are separated from the bodies. Here, the rectified capsules are delivered body-end first into the upper portion of split bushings or split filling rings. A vacuum applied from below pulls the bodies down into the lower portion of the split bushing. The diameter of the caps is too large to allow them to follow the bodies into the lower bushing portion. The split bushings are then separated to expose the bodies for filling. The body portion of the capsule can be thus filled with the fill mass which cannot exceed a temperature of 60° C. The cap and body bushing portions are rejoined wherein pins are used to push the filled bodies up into the caps for closure, and to push the closed capsules out of the bushings. Compressed air also may be used to eject the capsules. If necessary, hard gelatin capsules may be made hermetically by e.g. banding (i.e. layering down a film of gelatin, often distinctively colored, around the seam of the cap and body). [0007]
  • Using the above mentioned processes, however, it has been unfortunately found that shear sensitive fill masses can totally or partially solidify before being encapsulated, or even in the capsules upon storage. The solidification of the fill mass or of one or more components thereof is due to mechanical phenomena, such as the shear stress, which occurs at various points of the manufacturing process. The most critical points of the process involve the mixing vessels and the pumps, wherein the shear stress dramatically increases with increasing viscosity of the fill mass. [0008]
  • This total or partial solidification can cause significant and unacceptable changes in the pharmaceutical quality of the product like, for example, reduction and variability of the capsules dissolution rate, and hence the bioavailability of the drug substance and the therapeutic effects of the drug. [0009]
    • SUMMARY OF THE INVENTION
  • The present invention provides a process for encapsulating a shear sensitive fill mass into a capsule, comprising the following steps in order: [0010]
  • a) providing a shear sensitive fill mass comprising an agent taken from the group consisting of pharmaceutical active agents and nutrients; [0011]
  • b) heating the fill mass; [0012]
  • c) cooling the fill mass; and [0013]
  • d) encapsulating the fill mass into the capsule essentially immediately after said cooling. [0014]
  • The present invention provides a capsule containing a shear sensitive fill mass which comprises an agent selected from the group fo pharmaceutically active agents and nutrients, wherein the fill mass is encapsulated in accordance wth the above process. [0015]
  • The present invention also provides a capsule containing a shear sensitive fill mass which comprises an agent selected from the group of pharmaceutically active agents and nutrients, wherein the capsule has a constant dissolution rate of at least 70% of the pharmaceutically active agent within 30 minutes after administration.[0016]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1[0017] a is a flow sheet diagram depicting the process according to the invention for manufacturing soft gelatin capsules;
  • FIG. 1[0018] b is a flow sheet diagram depicting the process according to the invention for manufacturing hard gelatin capsules;
  • FIG. 2 is a rheogramm of the shear stress (Pa) over the shear rate (1/s) of three saquinavir soft gelatin capsules manufactured with the process of the invention; [0019]
  • FIG. 3 is a rheogramm of the shear stress (Pa) over the shear rate (1/s) of a saquinavir soft gelatin capsule (C[0020] 1) manufactured with the process of the invention, and of two saquinavir soft gelatin capsules (C2, C3) obtained with the conventional process;
  • FIG. 4 is the dissolution profile of three saquinavir soft gelatin capsules manufactured with the process of the invention; [0021]
  • FIG. 5 is the dissolution profile of a saquinavir soft gelatin capsule (C[0022] 1) manufactured with the process of the invention, and of two saquinavir soft gelatin capsules (C2, C3) obtained with the conventional process.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides a process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses obtained by said process. The fill mass comprises a pharmaceutically active agent or a nutrient. [0023]
  • The term “capsule” encompasses hard and soft shell capsules which are preferably used to administer nutrients or pharmaceutically active agents to individuals. Such capsules are soluble under physiological conditions, digestible or permeable. The capsule shells are usually made of gelatin, starch, or other suitable physiologically acceptable macromolecular materials in form of gels. Examples thereof are soft gelatin capsules, hard gelatin capsules and Hydroxy Propyl Methyl Cellulose (HPMC) capsules. [0024]
  • A shear sensitive fill mass which undergoes the process of the present invention can be an emulsion, dispersion or solution including a supersaturated solution. Suitable vehicles which can be used for preparing fill masses for encapsulation may be chosen among the aromatic and aliphatic hydrocarbons, chlorinated hydrocarbons, high-molecular-weight-alcohols, esters and organic acids, vegetable oils, mineral oil, silicon oil, non-ionic surface active agents, polyethylene glycols, medium chain triglycerides and medium chain mono and diglycerides, either alone or in combination. [0025]
  • The solid component of the shear sensitive fill mass, which has formed due to shear stress during the mixing and pumping stages of the process, can be re-liquefied or re-dissolved by heating it. The temperature to which the fill mass must be heated depends on the physical and chemical characteristics of the fill mass itself. The fill mass is then cooled to below about the sealing temperature for the type of capsule being used, so that the temperature of the fill mass is below the sealing temperature of the capsule when the fill mass is placed in the capsule. [0026]
  • Since the encapsulation temperature for soft and hard gelatin capsules should usually not exceed 35° C. and 60° C., respectively, the homogeneous fill mass is cooled to below the stated temperature for each type of gelatin capsule, preferably to about room temperature. It has been surprisingly found that, once cooled, the homogeneous shear sensitive fill mass does not return to the solid or semi-solid state as long as it does not undergo further mechanical strain. According to the present invention, the encapsulation takes place within a sufficiently short amount of time after the heating and subsequent cooling of the shear sensitive fill mass so that the content of the capsule remains homogeneous over the life time of the encapsulated nutrient or pharmaceutical agent. The heating and subsequent cooling of the fill mass takes place essentially immediately prior to encapsulation. For example, the amount of time from the cooling step to the encapsulation step can be from about 10 to 30 seconds, preferably from about 10 to about 20 seconds. The heating and cooling of the fill mass can be carried out in conventional manners, e.g. by letting it flow through spiral tubes immersed in water/oil baths and cold water bath, respectively. As the contact time of the fill mass in the heating device can be varied by modifying the residence time in the bath, heating of the fill mass after it has been processed through the dosing pump is also suitable for thermolabile substances. [0027]
  • The process according to the present invention allows one to obtain capsules showing high and constant dissolution rates. The amount of active agent encapsulated and administered to a patient can be therefore reduced since the active agent itself is rapidly dissolved. The overall costs of the medicaments are thereby also reduced. The high homogeneity (and therefore the high and constant dissolution rate) of the capsules produced with the process according to the present invention guarantees a reproducible bioavailability and therapeutic effect of an active agent which is contained in it. [0028]
  • In the case in which the capsule is made of soft gelatin, the fill mass is preferably heated to a temperature between 0° C. and about 20° C. above its melting point, and subsequently cooled to a temperature between about 35° C. and about 20° C. Where hard gelatin capsules are produced, the fill mass is preferably heated to a temperature between 0° C. and about 20° C. above its melting point, and subsequently cooled to a temperature between about 60° C. and about 20° C. [0029]
  • The process according to the present invention is suitable for fill masses like, for instance, emulsions, dispersions and solutions comprising the pharmaceutically active agent(s), as well as for pure pharmaceutically active agents in the liquid state. Particularly, the process according to the present invention is suitable for fill masses comprising high doses of a sparingly soluble pharmaceutical agent such as e.g. a HIV protease inhibitor and, more particularly, for solutions of saquinavir. These particular fill masses can be heated to a temperature which is preferably in the range between about 70° C. and about 100° C. and then cooled to a temperature between about 35° C. and about 20° C., in the case of soft gelatin capsules, and between about 60° C. and about 20° C. in the case of hard gelatin capsules. [0030]
  • Preferably, the process according to the present invention comprises the steps of: [0031]
  • a) feeding the fill mass into a feed tank; [0032]
  • b) feeding the fill mass from the feed tank into a dosing pump; [0033]
  • c) dosing the fill mass through a heater and then a cooler and into an injection wedge; [0034]
  • d) injecting the heated and subsequently cooled fill mass of step c) from the injection wedge into the capsules. [0035]
  • To advantage, the fill mass undergoes heating also in the feed tank, at a temperature which is preferably between about 35° C. and about 95° C. In this way solidification of the fill mass in the dosing pump can be avoided, and any complete or partial solidification of the fill mass that has occurred prior to the dosing pump can be reversed. In addition, heating of the feed tank reduces the viscosity of the fill mass and therefore reduces the risk and extent of solidification of the fill mass caused by shear stress in the dosing pump. [0036]
  • In accordance with a preferred embodiment of the present invention, the fill mass undergoes heating in the dosing pump, at a temperature which is preferably between about 35° C. and about 80° C. The heating of the dosing pump, e.g. electrically, avoids solidification of the fill mass in the dosing pump or reverses solidification of the fill mass that has occurred prior to the dosing pump. As the contact time of the fill mass in the dosing pump is short, heating of the latter is also suitable for thermolabile substances. [0037]
  • In a particularly preferred embodiment of the present invention, the fill mass is heated in the feed tank, as well as in the dosing pump, preferably at the above temperatures. [0038]
  • In accordance with the preferred process of the present invention, the fill mass which flows from the dosing pump is heated and then cooled. The dosed amounts are then passed into an injection wedge for subsequent injection into the capsules. [0039]
  • By using the process of the present invention, capsules are obtained wherein the shear sensitive fill mass remains highly homogeneous for at least six to twelve, or even up to about 24 months after production. The capsules obtained according to the process of the invention contain a shear sensitive fill mass and have a constant dissolution rate, and release of at least 70% of the drug substance is achieved within 30 minutes after administration. [0040]
  • The capsules according to the present invention contain a shear sensitive fill mass and which have a constant dissolution rate of at least 70% of the drug substance within 30 minutes after administration. [0041]
  • The fill mass preferably contains, as active ingredient, a HIV protease inhibitor and, more preferably, a solution of saquinavir. [0042]
  • By way of example, a preferred embodiment of the present invention is described with reference to the accompanying figures. [0043]
  • Referring now to FIGS. 1[0044] a and 1 b, the fill mass is prepared in a mixing vessel 1, wherein the active agent is dissolved, emulsified or suspended in an appropriate solvent, eventually together with antioxidants and/or other additives. The so obtained solution, emulsion or suspension, is transferred into a storage tank 2, and then pumped into a feed tank 3 and heated by a water bath. From the feed tank 3, the fill mass is fed by gravity to an electrically heated dosing pump 4 controlling the flow of the mass which will be injected in the capsules. The fill mass flowing out from the dosing pump 4 undergoes heating in a heating bath 5 (oil or water) and afterwards cooling in a cooling bath 6 (cold water) and is finally fed to a filling wedge 7 for injection into the capsule.
  • For the manufacture of soft gelatin capsules (FIG. 1[0045] a), gelatin mass is fed by gravity to a metering device 8 which controls the flow of the mass onto rotating drums (not shown). Gelatin ribbons 9 of controlled thickness are thus formed. The ribbons 9 are fed through a lubricant bath (not shown), over guide rolls (not shown) and then down between the wedge 7 and die rolls 10.
  • The fill mass is dosed, through orifices (not shown) of the wedge [0046] 7 into the gelatin ribbons 9 between the die rolls 10, wherein the orifices are lined up with die pockets 11 of the die rolls 10. The capsule is about half sealed when the pressure of the pumped fill mass forces the gelatin into the die pockets 11, where the capsules are simultaneously filled, shaped, hermetically sealed and cut from the gelatin ribbons 9. The sealing of the capsule is achieved by mechanical pressure on the die rolls 10 and by heating of the gelatin ribbons 9 by the wedge 7.
  • For the manufacture of hard gelatin capsules (FIG. 1[0047] b), the fill mass is dosed through orifices (not shown) of the wedge 7 into previously prepared hard gelatin shells 8. The filled hard gelatin capsules are then sealed.
    • EXAMPLE
  • Saquinavir gelatin capsules having the composition listed in Table 1 were prepared according to the process already described. [0048]
    TABLE 1a
    Composition of saquinavir soft gelatin capsule
    Ingredient mg/Capsule
    Capsule Fill:
    Saquinavir (amorphous) 200.00
    Medium Chain Mono and Diglycerides 765.00
    Povidone K 30 30.00
    DL-alpha-Tocopherol 5.00
    Mass of capsule contents 1000.00
    Capsule Shell:
    Gelatin 250.92
    Glycerol 85% 168.73
    Titanium Dioxide 3.06
    Yellow Iron Oxide 0.20
    Red Iron Oxide 0.027
    Mass of capsule shell 422.937
  • [0049]
    TABLE 1b
    Composition of saquinavir hard gelatin capsule
    Ingredient mg/Capsule
    Capsule Fill:
    Saquinavir (amorphous) 120.00
    Medium Chain Mono and Diglycerides 459.00
    Povidone K 30 18.00
    DL-alpha-Tocopherol 3.00
    Mass of capsule contents 600.00
    Capsule Shell:
    Gelatin 96.00
  • [0050]
    TABLE 2
    Temperature profile in the different plant units
    Plant unit Temperature profile
    Mixing vessel 1 (under 75-105 min at 63° C.
    stirring) 5 min at 83° C.
    cooling at 28° C.
    Storage tank
    2 25° C.
    Feed tank 3 (in water bath) 50° C. (bath)
    35-40° C. (fill mass)
    Dosing pump 4 50° C. (pump)
    40° C. (fill mass)
    Heating bath 5 90° C. (bath)
    to 90° C. within 2 min (fill mass)
    Cooling bath 6 20° C. (bath)
    to 30-25° C. (fill mass)
    Filling wedge 7 25° C. (fill mass)
  • The optical density and the light scattering of the capsule content (C) obtained with the process according to the invention were measured. Table 3 shows the values of the content (C) of three soft gelatin capsules obtained with the process of the invention and of the content of three soft gelatin capsules obtained with a conventional process (i.e., without heating the fill mass in the feed tank or in or after the dosing pump). [0051]
  • Table 3: Optical Density (540 nm, 5×5 mm cell) and Light Scattering (500/500 nm, 5×5 mm cell). [0052]
    Process according to
    Conventional Process the invention
    C1 C2 C3 C1 C2 C3
    Optical Density 0.862 1.391 0.343 0.010 0.014 0.008
    Light Scattering 34.3 23.8 23.8 0.010 0.010 0.000
  • As shown in Table 3, the optical density and the light scattering values of the capsule content produced according to the above process are much lower than those obtained with conventional processes and, they are highly reproducible. The saquinavir capsules of Table 3 obtained with the process of the present invention are therefore superior in their homogeneity and limpidity as compared to those obtained with conventional processes. [0053]
  • In FIGS. 2 and 3 (C[0054] 1) it can moreover be seen that the fill masses of the capsules obtained with the above process are Newtonian liquids, i.e., there is a linear relationship between shear rate and shear stress wherein the flow curves are linear from the origin, whereas the fill masses of capsules manufactured with conventional processes do not show such a behaviour (FIG. 3, C2, C3).
  • The saquinavir capsules obtained with the process of the present invention strongly improve their dissolution rate, as compared with conventional capsules. FIG. 5 depicts the much faster dissolution rate of C[0055] 1, a capsule according to the invention, as compared to the dissolution rate of C2 and C3 which are two capsules made with the conventional technique. FIG. 4 depicts the dissolution profile of three saquinavir soft gelatin capsules manufactured in accordance with the process of the present invention. The dissolution rate of the present saquinavir gelatin capsules is highly reproducible, as clearly shown in FIG. 4.

Claims (20)

What is claimed is:
1. A process for encapsulating a shear sensitive fill mass into a capsule, comprising the following steps in order:
a) providing a shear sensitive fill mass comprising an agent taken from the group consisting of pharmaceutical active agents and nutrients;
b) heating the fill mass;
c) cooling the fill mass; and
d) encapsulating the fill mass into the capsule essentially immediately after said cooling.
2. The process according to claim 1, wherein the capsule is taken from the group consisting of a soft gelatin capsule, a hard gelatin capsule and a HPMC capsule.
3. The process according to claim 2, wherein the capsule is a soft gelatin capsule and the fill mass is heated to a temperature between 0° C. and about 20° C. above its melting point, and cooled to a temperature between about 35° C. and about 20° C.
4. The process according to claim 2, wherein the capsule is a hard gelatin capsule and the fill mass is heated to a temperature between 0° C. and about 20° C. above its melting point, and subsequently cooled to a temperature between about 60° C. and about 20° C.
5. The process according to claim 1, wherein the fill mass comprises a HIV protease inhibitor and said fill mass is heated to a temperature between about 70° C. and about 100° C.
6. The process according to claim 1, wherein the fill mass provided in step a) is in a form taken from the group consisting of emulsions, dispersions and solutions.
7. The process according to claim 6, wherein the fill mass provided in step a) is a solution comprising saquinavir.
8. The process according to claim 1, further comprising prior to step b), transporting the fill mass through a pump, to control the flow rate of the fill mass.
9. The process according to claim 8, wherein the fill mass in said pump is heated.
10. The process according to claim 9, wherein the fill mass in said pump is heated to between about 35° C. and about 80° C.
11. The process according to claim 1, further comprising prior to step b), placing the pharmaceutical fill mass in a chamber and feeding the fill mass from the chamber to a heating unit.
12. The process according to claim 11, wherein the fill mass in said chamber is heated.
13. The process according to claim 12, wherein the fill mass in said chamber is heated to a temperature between about 35° C. and about 95° C.
14. A process for encapsulating a shear sensitive fill mass into a capsule comprising the following steps in order:
a) mixing a shear sensitive fill mass comprising an agent selected from the group consisting of pharmaceutical active agents and nutrients;
b) heating the fill mass in a chamber;
c) transporting the fill mass from the chamber to a pump;
d) heating the fill mass in the pump;
e) controlling the flow of the fill mass from the pump;
f) heating the fill mass from the pump;
g) cooling the fill mass; and
h) encapsulating the fill mass into the capsule essentially immediately after said cooling.
15. A capsule containing a shear sensitive fill mass which comprises an agent taken from the group consisting of pharmaceutically active agents and nutrients, wherein said fill mass is encapsulated in accordance with the process of claim 1.
16. The capsule according to claim 15, wherein said agent is saquinavir.
17. A capsule containing a shear sensitive fill mass which comprises an agent selected from the group consisting of pharmaceutically active agents and nutrients, said capsule having a constant dissolution rate of said agent of at least 70% within 30 minutes after administration.
18. The capsule according to claim 17, wherein said agent is saquinavir.
19. A capsule containing a shear sensitive fill mass which comprises an agent selected from the group consisting of pharmaceutical agents and nutrients, wherein the fill mass has a linear relationship between shear rate and shear stress from the origin of a plot of such relationship.
20. The capsule according to claim 19, wherein said agent is saquinavir.
US09/440,731 1998-11-17 1999-11-16 Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses Expired - Lifetime US6352717B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98121831 1998-11-17
EP98121831.6 1998-11-17
EP98121831 1998-11-17

Publications (2)

Publication Number Publication Date
US20020006417A1 true US20020006417A1 (en) 2002-01-17
US6352717B2 US6352717B2 (en) 2002-03-05

Family

ID=8232985

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/440,731 Expired - Lifetime US6352717B2 (en) 1998-11-17 1999-11-16 Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses

Country Status (35)

Country Link
US (1) US6352717B2 (en)
EP (1) EP1131037B1 (en)
JP (1) JP3623166B2 (en)
KR (1) KR100446118B1 (en)
CN (1) CN1172649C (en)
AR (1) AR020013A1 (en)
AT (1) ATE274895T1 (en)
AU (1) AU751446B2 (en)
BR (1) BR9915444B1 (en)
CA (1) CA2350943C (en)
CO (1) CO5150161A1 (en)
CZ (1) CZ299800B6 (en)
DE (1) DE69919889T2 (en)
DK (1) DK1131037T3 (en)
ES (1) ES2228141T3 (en)
HK (1) HK1042227B (en)
HR (1) HRP20010341A2 (en)
HU (1) HU226498B1 (en)
ID (1) ID30128A (en)
IL (2) IL143119A0 (en)
MA (1) MA26761A1 (en)
MY (1) MY120081A (en)
NO (1) NO20012384D0 (en)
NZ (1) NZ511663A (en)
PE (1) PE20001240A1 (en)
PL (1) PL190382B1 (en)
PT (1) PT1131037E (en)
RU (1) RU2219911C2 (en)
SI (1) SI1131037T1 (en)
TR (1) TR200101358T2 (en)
TW (1) TWI221767B (en)
UY (1) UY25803A1 (en)
WO (1) WO2000028942A1 (en)
YU (1) YU33001A (en)
ZA (1) ZA200103891B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247010B2 (en) 2003-10-01 2007-07-24 Technophar Equipment & Service Limited Servo control for capsule making machine
EP2042180A1 (en) * 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Preparations containing phytosterol

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60019334T2 (en) * 1999-12-09 2005-09-08 Alza Corp., Mountain View ANTIVIRAL ARZNEI
GB0027954D0 (en) * 2000-11-16 2001-01-03 Mw Encap Ltd Liquid filled capsules
DE50012405D1 (en) * 2000-12-20 2006-05-11 Swiss Caps Rechte & Lizenzen Rotary die method and filling wedge for producing capsules, in particular soft capsules
GB0712972D0 (en) * 2007-07-04 2007-08-15 Glaxosmithkline Consumer Healt Formulation
EP2393386A1 (en) * 2009-02-04 2011-12-14 Kalamazoo Holdings, Inc. Compositions and methods for enhancing the stability of foods, beverages, nutritional supplements and cosmetics
EP2410970B1 (en) * 2009-03-26 2013-02-13 Swiss Caps Rechte und Lizenzen AG New device for manufacturing soft capsules
WO2013031972A1 (en) * 2011-09-02 2013-03-07 株式会社三協 Pump unit of capsule manufacturing apparatus for supplying capsule liquid, capsule manufacturing apparatus applying the pump unit, method for capsule manufacturing applying same, capsule manufactured by same
US10568811B2 (en) * 2016-02-22 2020-02-25 R.P. Scherer Technologies, Llc Multiple-fluid injection pump
CN109645530A (en) * 2019-01-09 2019-04-19 安徽亳药千草国药股份有限公司 It is a kind of for the encapsulating machine of Se-rich lucid ganoderma spore oil to be perfused

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2692404A (en) * 1949-12-07 1954-10-26 Gennell Capsulations Inc Method and apparatus for forming capsules
JPS56163656A (en) * 1980-05-22 1981-12-16 Nippon Elanco Device for filling hard gelatin capsule with viscous substance
US4656066A (en) * 1982-12-20 1987-04-07 Warner-Lambert Company Apparatus and method for sealing capsules
JPS59131355A (en) * 1983-01-17 1984-07-28 森下仁丹株式会社 Multiple soft capsule
US4609403A (en) * 1984-03-12 1986-09-02 Warner-Lambert Company Foam soft gelatin capsules and their method of manufacture
DE8536337U1 (en) * 1985-12-23 1986-02-13 R.P. Scherer GmbH, 6930 Eberbach Filling wedge for a machine for the production of gelatine capsules
FI80828C (en) * 1988-04-08 1990-08-10 Piscina Oy ANORDINATION FOR THE END OF VAT.
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
EP0649651B1 (en) * 1993-09-28 2000-12-13 R.P. Scherer GmbH Soft gelatin capsule manufacture
GB9403449D0 (en) * 1994-02-23 1994-04-13 Wellcome Found Therapeutic benzonitriles
KR960016371U (en) * 1994-11-11 1996-06-17 김덕흥 Gelatin Sheet Cooling System of Soft Gelatin Capsule Maker

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247010B2 (en) 2003-10-01 2007-07-24 Technophar Equipment & Service Limited Servo control for capsule making machine
EP2042180A1 (en) * 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Preparations containing phytosterol

Also Published As

Publication number Publication date
JP2002529200A (en) 2002-09-10
JP3623166B2 (en) 2005-02-23
EP1131037A1 (en) 2001-09-12
MA26761A1 (en) 2004-12-20
NZ511663A (en) 2003-08-29
ATE274895T1 (en) 2004-09-15
KR20010075711A (en) 2001-08-09
DE69919889T2 (en) 2005-09-15
ES2228141T3 (en) 2005-04-01
ZA200103891B (en) 2002-08-14
PL190382B1 (en) 2005-12-30
CZ299800B6 (en) 2008-11-26
TWI221767B (en) 2004-10-11
IL143119A0 (en) 2002-04-21
AU751446B2 (en) 2002-08-15
HRP20010341A2 (en) 2002-06-30
CN1172649C (en) 2004-10-27
AR020013A1 (en) 2002-03-27
EP1131037B1 (en) 2004-09-01
NO20012384L (en) 2001-05-15
YU33001A (en) 2004-05-12
UY25803A1 (en) 2000-08-21
KR100446118B1 (en) 2004-08-30
NO20012384D0 (en) 2001-05-15
HUP0104464A3 (en) 2006-06-28
DK1131037T3 (en) 2005-01-10
CZ20011644A3 (en) 2001-08-15
HU226498B1 (en) 2009-03-02
PE20001240A1 (en) 2000-11-14
DE69919889D1 (en) 2004-10-07
PT1131037E (en) 2004-12-31
MY120081A (en) 2005-08-30
AU1775100A (en) 2000-06-05
BR9915444B1 (en) 2013-10-22
CA2350943A1 (en) 2000-05-25
WO2000028942A1 (en) 2000-05-25
IL143119A (en) 2007-05-15
BR9915444A (en) 2001-08-07
HK1042227B (en) 2005-03-18
CO5150161A1 (en) 2002-04-29
ID30128A (en) 2001-11-08
TR200101358T2 (en) 2001-12-21
CA2350943C (en) 2006-06-20
RU2219911C2 (en) 2003-12-27
HK1042227A1 (en) 2002-08-09
US6352717B2 (en) 2002-03-05
PL348350A1 (en) 2002-05-20
CN1326335A (en) 2001-12-12
HUP0104464A2 (en) 2002-03-28
SI1131037T1 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
US11766445B2 (en) Oral soft gel capsule containing psychedelic compound
US4450877A (en) Pharmaceutical preparations in solid unit dosage form
US6352717B2 (en) Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses
JPS62114911A (en) Oral administration type slow release medicine
AU718160B2 (en) Soft gelatin capsules containing particulate material
US6248354B1 (en) Capsule system
US4497157A (en) Process for filling pharmaceutical products containing phospholipides and highly viscous at room temperature, into hard capsules
EP2976068B1 (en) Pharmaceutical compositions comprising an active agent
Rowley Filling of liquids and semi-solids into hard two-piece capsules
Jones et al. Capsule shell manufacture
Moon et al. Formulation and In-Vitro Characterization Of Calcitriol Soft Gelatin Capsule
Podczek Technology to manufacture soft capsules
EP2949319A1 (en) Pharmaceutical compositions comprising an active agent
Pitt Formulation and processing for powder sachets
NZ753003A (en) Multiple-fill/chamber softgel die
KR20170022553A (en) Soft capsule containing solid formulation as core ingredient
MXPA06000100A (en) Controlled release preparations

Legal Events

Date Code Title Description
AS Assignment

Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F.HOFFMANN-LA ROCHE AG;REEL/FRAME:010660/0866

Effective date: 20000121

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALEX, RAINER;GERHARDS, JURGEN;KRAEMER-PITTROF, INGEBORG;AND OTHERS;REEL/FRAME:010663/0216;SIGNING DATES FROM 19991230 TO 20000112

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12